Considerations in pharmacotherapeutic treatment of movement disorders after traumatic brain injury.
National Center for Neurogenic Communication Disorders, University of Arizona, Tucson 85721.
L S
LS
Turkstra
D001930:Brain Injuries / Q000150:complications / Q000503:physiopathology*; D002540:Cerebral Cortex / Q000503:physiopathology; D003072:Cognition Disorders / Q000150:complications / Q000175:diagnosis; D015259:Dopamine Agents / Q000145:classification / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009048:Motor Skills; D009069:Movement Disorders / Q000188:drug therapy* / Q000209:etiology; D009434:Neural Pathways
D015259:Dopamine Agents